Wesbanco Bank Inc. Acquires New Position in Exelixis, Inc. $EXEL

Wesbanco Bank Inc. acquired a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL) in the third quarter, HoldingsChannel reports. The fund acquired 28,034 shares of the biotechnology company’s stock, valued at approximately $1,158,000.

Several other hedge funds have also recently bought and sold shares of the business. TriaGen Wealth Management LLC acquired a new position in shares of Exelixis in the third quarter valued at $2,024,000. Allianz Asset Management GmbH grew its position in Exelixis by 153.3% during the 3rd quarter. Allianz Asset Management GmbH now owns 2,462,948 shares of the biotechnology company’s stock worth $101,720,000 after acquiring an additional 1,490,520 shares during the last quarter. Candriam S.C.A. grew its holdings in shares of Exelixis by 18.4% during the third quarter. Candriam S.C.A. now owns 696,104 shares of the biotechnology company’s stock worth $28,749,000 after purchasing an additional 108,367 shares during the last quarter. BridgePort Financial Solutions LLC acquired a new stake in Exelixis in the 3rd quarter valued at about $517,000. Finally, Fox Run Management L.L.C. acquired a new position in Exelixis during the 2nd quarter worth $321,000. 85.27% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently commented on EXEL shares. Barclays lifted their price target on shares of Exelixis from $41.00 to $44.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 4th. Wells Fargo & Company lowered their target price on Exelixis from $36.00 to $30.00 and set an “equal weight” rating for the company in a report on Tuesday, October 21st. Wolfe Research initiated coverage on shares of Exelixis in a research report on Tuesday, November 18th. They issued a “peer perform” rating for the company. Zacks Research upgraded shares of Exelixis from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 4th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Exelixis in a research report on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $46.16.

Insider Activity

In related news, EVP Patrick J. Haley sold 34,187 shares of Exelixis stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $41.88, for a total value of $1,431,751.56. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders sold 72,230 shares of company stock worth $3,046,923 in the last ninety days. 2.85% of the stock is owned by company insiders.

Key Stories Impacting Exelixis

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Q4 earnings beat: Exelixis reported Q4 EPS above consensus (reported $0.94 vs. estimates around $0.74–$0.77), reflecting margin improvement and stronger profitability year‑over‑year. Exelixis (EXEL) Q4 Earnings and Revenues Beat Estimates
• Positive Sentiment: Balance sheet & cash flow strength: operating cash generation and cash balances improved materially (cash and equivalents rose, strong operating cash flow), which supports reinvestment and pipeline funding. Exelixis (EXEL) Releases Q4 2025 Earnings
• Positive Sentiment: Analyst support: William Blair and other firms have reiterated bullish stances / buy ratings, citing solid execution and advancing pipeline that underpin 2026 earnings power. Analyst backing can buoy sentiment even after mixed results. Exelixis: Solid Q4 Execution and Advancing Pipeline Underpin Buy Rating and 2026 Earnings Power
• Neutral Sentiment: Corporate update / outlook: Management presented a slide deck and described progress on the cabozantinib franchise and clinical milestones, positioning the company for growth in 2026 — an update investors will parse for timing of launches and label expansions. Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
• Neutral Sentiment: Positive media/valuation mentions: Exelixis surfaced in value/PEG screens and retail pieces highlighting it as a sub‑$50 healthcare pick, which may attract long‑only and retail interest. 4 Discounted PEG Value Stocks to Boost Your Portfolio’s Health
• Negative Sentiment: Revenue shortfall vs. some estimates: total Q4 revenue rose year‑over‑year but came in below certain consensus figures (~$598.7M reported vs. higher street estimates), which likely tempered upside from the EPS beat. Exelixis (EXEL) Releases Q4 2025 Earnings
• Negative Sentiment: Insider selling & mixed price targets: recent filings show several insider sales and a wide range of analyst targets (some low), which can create caution among investors despite overall bullish coverage. Exelixis (EXEL) Releases Q4 2025 Earnings
• Neutral Sentiment: Short‑interest data in the newsfeed appears garbled/insignificant; it is not a clear driver in this update. (No reliable days‑to‑cover signal provided.)

Exelixis Trading Down 2.2%

EXEL stock opened at $42.98 on Wednesday. The firm has a 50-day moving average price of $43.69 and a 200-day moving average price of $40.92. The stock has a market capitalization of $11.52 billion, a P/E ratio of 18.14, a price-to-earnings-growth ratio of 0.74 and a beta of 0.42. Exelixis, Inc. has a 12 month low of $32.38 and a 12 month high of $49.62.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 EPS for the quarter, beating the consensus estimate of $0.74 by $0.20. Exelixis had a return on equity of 31.06% and a net margin of 29.63%.The firm had revenue of $598.66 million during the quarter, compared to the consensus estimate of $609.17 million. During the same period last year, the company earned $0.55 earnings per share. The business’s quarterly revenue was up 5.6% on a year-over-year basis. As a group, equities analysts predict that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.